Notch Signaling in Cancer: Rationale and Strategies for Targeting

被引:24
作者
Alketbi, Aisha [1 ]
Attoub, Samir [1 ,2 ]
机构
[1] United Arab Emirates Univ, Coll Med & Hlth Sci, Dept Pharmacol & Therapeut, Al Ain, U Arab Emirates
[2] INSERM, Paris, France
基金
新加坡国家研究基金会;
关键词
Cancer; monoclonal antibodies; notch inhibitors; notch signaling; gamma-secretase inhibitors; GAMMA-SECRETASE INHIBITORS; ADVANCED SOLID TUMORS; HUMAN BREAST-CANCER; PHASE-I; PANCREATIC-CANCER; STEM-CELLS; PATHWAY; ANGIOGENESIS; THERAPY; GROWTH;
D O I
10.2174/156800961505150710113353
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The Notch signaling pathway is a highly conserved system that controls embryonic cell fate decisions and the maintenance of adult stem cells through affecting communication between adjacent cells. The pathway is linked to the development of various cancers owing to increased cell proliferation and tumor blood perfusion in addition to inhibition of apoptosis. Pharmaceutical agents that suppress overactive Notch signaling may be of benefit in the treatment of patients with various cancers. These targeted therapies confer several advantages over conventional anticancer therapies including reduced deleterious effects on normal cells. In this review, we explore the rationale for targeting the Notch signaling pathway in cancer along with different investigational strategies designed to block the pathway.
引用
收藏
页码:364 / 374
页数:11
相关论文
共 94 条
[1]   Non-canonical Notch signaling: emerging role and mechanism [J].
Andersen, Peter ;
Uosaki, Hideki ;
Shenje, Lincoln T. ;
Kwon, Chulan .
TRENDS IN CELL BIOLOGY, 2012, 22 (05) :257-265
[2]  
[Anonymous], 2014, GAMMA SECRETASE NOTC
[3]  
[Anonymous], 2014, RO4929097 ERLOTINIB
[4]  
[Anonymous], 2011, Study to Evaluate Safety, Tolerability, and Antimicrobial Activity of Single
[5]  
[Anonymous], 2014, MULTIPLE ASCENDING D
[6]  
[Anonymous], 2012, STUDY LY3039478 PART
[7]  
[Anonymous], 2013, STUDY GEMCITABINE DE
[8]  
[Anonymous], 2006, PHASE 1 STUDY GAMMA
[9]  
[Anonymous], 2009, PHASE 1 TRIAL PF 030
[10]  
[Anonymous], 2012, PHASE 1 DOSE ESCALAT